Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05256251

Westlake Longevity Cohort

The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians and senior citizens living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. The second aim is to culture the gut microbiota of these elderly people through culturomics. The third aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Aging

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease, and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity is influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome, and genetics. At present, research on healthy longevity is mainly focused on Drosophila, nematodes, and mouse models, but few studies have targeted longevity populations. Centenarians and nonagenarians are the best populations to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanisms of healthy longevity in humans are still unclear. Therefore, the We-Longevity design includes centenarians, nonagenarians, and senior citizens. We will determine the fecal/serum metabolome, culturable gut microbiome characteristics, gut microbiome, serum proteome, and genome, together with diet, lifestyle, and disease information.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants live in Lishui, China.
  • Participants intend to remain in Lishui for ≥3 years.

Exclusion criteria

  • Participants with infectious diseases.

Treatment and study plan

Primary outcomes

  1. Physical frailty

    Time frame: 36 months

    Physical frailty will be evaluated by using Fried's criteria.

  2. Gut microbiome

    Time frame: 36 months

    Fecal microbiome will be analyzed by 16S/ITS rRNA gene sequencing and metagenome sequencing. Furthermore, fecal microbiota will be cultured, picked and identified.

Secondary outcomes

  1. Cognitive function

    Time frame: 36 months

    Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).

  2. Blood biochemical parameters

    Time frame: 36 months

    Blood biochemical parameters (e.g., glucose and lipids) will be analyzed by an automated biochemical analyzer.

  3. Metabolomics profiling

    Time frame: 36 months

    Blood and fecal metabolomics will be analyzed by LC-MS/MS.

Study contacts

Contact information is provided by the study sponsor or research team.

Ju-Sheng Zheng, PhD

CONTACT

[email protected]

86-0571-86915303

Junhui Zhang, PhD

CONTACT

[email protected]

86-0571-86915303

Sponsors and collaborators

Lead sponsor

Westlake University

Other

Registry information

Acronym: We-Longevity

Important dates

Study start
2021
Primary completion
2025
Study completion
2031
First posted
Feb 25, 2022
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.